Meeting
2011 ASCO Annual Meeting
Phase I trial of bevacizumab combined with concurrent chemoradiation for squamous cell carcinoma of the head and neck: Preliminary outcome results.
Authors
P. M. Harari
University of Wisconsin Carbone Cancer Center, Madison, WI
P. M. Harari , D. Khuntia , A. M. Traynor , T. Hoang , D. T. Yang , G. K. Hartig , T. M. McCulloch , R. Jeraj , M. J. Nyflot , P. A. Wiederholt , L. R. Gentry
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Head and Neck Cancer
Clinical Trial Registration Number
1234567
Citation
J Clin Oncol 29: 2011 (suppl; abstr 5518)
Abstract #
5518
Poster Bd #
12
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
A phase I study of the PI3K inhibitor buplarlisib (B) with concurrent chemoradiotherapy (CRT) in patients with high risk locally advanced squamous cell cancer of the head and neck (LASCCHN).
First Author: Jochen H. Lorch
Poster
2022 ASCO Annual Meeting
The RADIO trial: Randomized assessment of cisplatin dosing interval for ototoxicity with curative concurrent chemo-radiation for locally advanced head and neck squamous cell carcinoma.
First Author: Sara Kuruvilla
Poster
2018 ASCO Annual Meeting
A phase I dose-finding study of metformin in combination with concurrent cisplatin and radiation in patients with locally advanced head and neck squamous cell carcinoma.
First Author: Shuchi Gulati
Poster
2016 ASCO Annual Meeting
ORCA-2: A phase I study of olaparib in addition to cisplatin-based concurrent chemoradiotherapy for patients with high risk locally advanced squamous cell carcinoma of the head and neck.
First Author: Martin David Forster